Novo Nordisk Offers Discounted Wegovy Plan

Novo Nordisk has introduced a new discounted subscription plan for its popular weight-loss drug, Wegovy, within the United States. This initiative aims to improve patient access to the medication, potentially increasing its adoption and market penetration. By offering a more affordable option, Novo Nordisk is likely seeking to capture a larger share of the growing obesity treatment market. The move could also signal a broader trend towards innovative pricing models in the pharmaceutical sector to address cost concerns and enhance patient adherence to long-term therapies.